Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

NIH Selects Essex Management to Advance Scientific Computing for the National Cancer Institute

ROCKVILLE, Md., Oct. 28, 2021 /PRNewswire-PRWeb/ -- Essex Management, LLC announced today it won a highly competitive position on Biomedical Information Technology, Software Development, and Informatics Support (BITSDIS). This five-year Indefinite-Delivery Indefinite-Quantity (IDIQ) contract, worth up to $350 million, supports the National Institutes of Health (NIH) National Cancer Institute (NCI) Center for Biomedical Informatics and Information Technology (CBIIT). Essex also won two of the first three task orders issued by NCI.

BITSDIS helps CBIIT respond to the technology and scientific computing needs of many programs at the NCI, including:

Essex will provide multidisciplinary teams of project and contract managers, computational biologists, software developers, cloud systems security professionals and engineers, architects and system designers, user design experts, and analysts to support two task orders: Clinical Reporting and Research Informatics (CRRI) Support Services, and Clinical Trials Reporting Office (CTRO) Support Services. Under these task orders Essex will:



"Essex teams help improve the lives of cancer patients by rapidly delivering leading-edge technology solutions to advance cancer research," said Kevin Hurley, Essex CEO. "This award strengthens our long relationship with NCI and shows that NCI values our approach. We bring together engineers, designers, bioinformaticians, clinical experts, and project managers to solve the complex technical and data challenges of precision medicine, clinical trials, and scientific computing needs facing the cancer research community."

These task orders also help the NCI work towards the goal of building a FAIR (Findable, Accessible, Interoperable, and Reusable) data ecosystem that facilitates new discoveries in proteomic, genomic, and immunologic drivers of cancer, and leads to novel treatment options for all cancer patients.

About Essex Management Essex Management is a biomedical informatics and health information technology small business firm that offers tailored consulting services and leading-edge technology solutions. At Essex, multidisciplinary teams of engineers, business analysts, and project managers work with computational biologists and clinical experts to navigate the deep waters of scientific computing to save lives and improve the quality of care. Since 2009, we have been a technology catalyst by strategically developing and managing complex health and biomedical information programs for the Federal Government, research institutions, and the private sector.

Media Contact
David Loose, Chief Business Officer, mailto:david.loose@essexmanagement.com

Media Contact

David Loose, Chief Business Officer, Essex Management, 1 301.760.7527, info@essexmanagement.com


SOURCE Essex Management

These press releases may also interest you

at 00:04
Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, held an award ceremony with the British...

at 00:01
U.S. News & World Report today published the inaugural edition of the Best Hospitals for Maternity, which expands the U.S. News Best Hospitals rankings, ratings and data offerings. This expansion builds upon more than 32 years of guiding patients and...

6 déc 2021
Today Stride Health, the leader in portable benefits for independent workers, announced its support of the "Gig Workers' Week of Action" initiative by the Centers for Medicare & Medicaid Services (CMS) to help raise awareness among independent...

6 déc 2021
The healthcare logistics market in Canada is expected to observe substantial growth during the forecast period. The government of Canada has been investing in enhancing the logistics infrastructure across the country, which is subsequently driving...

6 déc 2021
On December 9th, children visiting Adventure Dental and Vision in Aurora will have a new friend ? Robin the Robot! Designed for children by scientists, engineers, and pediatric psychologists, Robin is the first of its kind emotionally intelligent...

6 déc 2021
Today, Akeso, Inc. (9926.HK) announced that the company will support an investigator-initiated study (IIS) to evaluate the efficacy and safety of Akeso's novel, first-in-class anti-PD-1/CTLA-4 bispecific antibody, cadonilimab, for the treatment of...

News published on 28 october 2021 at 10:15 and distributed by: